Immunic (NASDAQ:IMUX) Given "Buy" Rating at B. Riley

B. Riley reissued their buy rating on shares of Immunic (NASDAQ:IMUX - Free Report) in a research note released on Wednesday,Benzinga reports. The brokerage currently has a $6.00 price target on the stock. B. Riley also issued estimates for Immunic's Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.75) EPS.

IMUX has been the subject of a number of other research reports. D. Boral Capital reiterated a "buy" rating and set a $17.00 target price on shares of Immunic in a research note on Thursday, April 10th. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. William Blair started coverage on shares of Immunic in a research note on Tuesday, March 25th. They set an "outperform" rating on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Immunic in a research report on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Immunic has an average rating of "Buy" and a consensus price target of $13.20.

Immunic Price Performance

IMUX traded up $0.01 on Wednesday, reaching $0.99. 471,465 shares of the company's stock were exchanged, compared to its average volume of 625,368. The stock's fifty day moving average price is $1.08 and its 200-day moving average price is $1.14. The stock has a market cap of $94.77 million, a PE ratio of -0.80 and a beta of 1.91. Immunic has a twelve month low of $0.83 and a twelve month high of $2.11.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently added to or reduced their stakes in the company. State Street Corp lifted its position in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after acquiring an additional 11,642 shares in the last quarter. Jane Street Group LLC boosted its position in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after purchasing an additional 38,553 shares during the period. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at about $50,000. HB Wealth Management LLC acquired a new stake in Immunic during the 4th quarter worth approximately $81,000. Finally, Invesco Ltd. acquired a new position in shares of Immunic in the fourth quarter valued at about $37,000. Institutional investors own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.